TYK Medicines, Inc. Class H (2410) AI Stock Analysis

• Market Cap: HK$4.38B
• Dividend Yield: N/A
• Average Volume (3M): 14.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 153
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.55
• Shares Outstanding: 380,065,830
• 10 Day Avg. Volume: 4,737,687
• 30 Day Avg. Volume: 14,019,805
• PEG Ratio: -3.32
• Price to Book (P/B): 31.87
• Price to Sales (P/S): 139726.58
• P/FCF Ratio: -39.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.78
• Revenue Forecast (FY): HK$504.00M

• Rating: 46 Neutral
• Price Target: HK$13.50 ▲(4.41% Upside)
• Action: Reiterated Date: 01/08/26
• Date: Action: Reiterated 01/08/26

The score is primarily held down by very weak financial performance: persistent large losses and sustained, worsening cash burn with minimal/volatile revenue. Technical indicators are mixed but slightly improved in the near term (above 20D/50D with neutral-to-positive RSI), providing only limited support. Valuation impact is neutral due to missing P/E and dividend yield data.

Positive Factors

Improved 2024 Capitalization

Positive shareholders' equity and moderate leverage in 2024 materially improve solvency versus prior years, giving the company more flexibility to fund development programs and survive funding gaps. This stronger capitalization reduces near-term default risk and supports longer-term strategic options.

Negative Factors

Persistent Negative Operating Cash Flow

Consistent, worsening operating cash burn means the business consumes substantial cash to operate, forcing reliance on external funding. Over months this pressures liquidity, risks dilutive capital raises, and limits the firm's ability to fund R&D or commercialization organically without altering strategy.

TYK Medicines, Inc. Class H Business Overview & Revenue Model

Company Description

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a th...

Read more

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a th...

TYK Medicines, Inc. Class H Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	107.00K	0.00	44.24M
Gross Profit	0.00	14.00K	0.00	20.04M
EBITDA	-199.38M	-346.03M	-346.80M	-292.22M
Net Income	-219.05M	-386.95M	-382.43M	-310.99M
Balance Sheet
Total Assets	529.30M	915.69M	573.14M	558.36M
Cash, Cash Equivalents and Short-Term Investments	158.31M	435.46M	192.83M	243.49M
Total Debt	120.72M	176.85M	1.33B	82.33M
Total Liabilities	1.57B	443.13M	1.45B	1.06B
Stockholders Equity	-1.05B	469.09M	-973.82M	-505.94M
Cash Flow
Free Cash Flow	-154.55M	-381.87M	-278.20M	-308.23M
Operating Cash Flow	-136.28M	-308.25M	-200.94M	-220.05M
Investing Cash Flow	-120.14M	-135.86M	73.01M	-158.16M
Financing Cash Flow	114.65M	632.08M	224.00M	351.14M

TYK Medicines, Inc. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	HK$7.43B	6.31	11.90%	5.80%	-20.64%	-25.39%
2256	57 Neutral	HK$8.94B	135.64	11.21%	―	23.37%	―
1951	55 Neutral	HK$6.86B	-6.17	-10.66%	2.38%	-8.56%	-403.12%
1672	54 Neutral	HK$18.61B	-22.61	-12.74%	―	-76.58%	-4.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$12.67B	5.89	18.28%	―	59.70%	239.97%
2410	46 Neutral	HK$4.38B	―	153.33%	―	―	―

TYK Medicines, Inc. Class H Corporate Events